TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma

Sequential single cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin's lymphoma

(2022) Zachary Jackson et al.   Cancer Discovery

Tumor interferon signaling and suppressive myeloid cells associate with CAR T cell failure in large B cell lymphoma

(2021) Michael D. Jain et al.   BLOOD

Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer

(2021) Gang Xin et al.   Cancer Immunology Research

Myeloid-derived suppressor cells (MDSC): When good intentions go awry

(2021) Maria Dulfary Sanchez-Pino et al.   CELLULAR IMMUNOLOGY

Mechanisms of response and resistance to CAR T cell therapies

(2021) Trisha R Berger et al.   CURRENT OPINION IN IMMUNOLOGY

MDSC: Markers, development, states, and unaddressed complexity

(2021) Samarth Hegde et al.   IMMUNITY

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma

(2021) Shaojun Zhang et al.   Nature Communications

IFNg is Critical for CAR T Cell Mediated Myeloid Activation and Induction of Endogenous Immunity

(2021) Darya Alizadeh et al.   Cancer Discovery

Integrative bulk and single-cell profiling of pre-manufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy

(2021) Gregory M Chen et al.   Cancer Discovery

A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity

(2021) Morgane Boulch et al.   Science Immunology

Screening and monitoring of the BTK C481S mutation in a real‐world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy

(2021) Csaba Bödör et al.   BRITISH JOURNAL OF HAEMATOLOGY

Deregulation of HLA-I in cancer and its central importance for immunotherapy

(2021) Ahmet Hazini et al.   Journal for ImmunoTherapy of Cancer

MDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer

(2021) Christophe Vanhaver et al.   Journal of Clinical Medicine

Targeting cytokine and therapy induced PIM1 activation in T-cell acute lymphoblastic leukemia and lymphoma

(2020) Renate De Smedt et al.   BLOOD

Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction

(2020) Nathan Singh et al.   Cancer Discovery

Tumor-Associated Macrophages: Recent Insights and Therapies

(2020) Jiawei Zhou et al.   Frontiers in Oncology

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

(2020) Michael Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tuning the Antigen Density Requirement for CAR T-cell Activity

(2020) Robbie G. Majzner et al.   Cancer Discovery

Role of Tumor-Associated Myeloid Cells in Breast Cancer

(2020) Yoon Jin Cha et al.   Cells

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

(2020) Qing Deng et al.   NATURE MEDICINE

Cytokine profiling in serum-derived exosomes isolated by different methods

(2020) Hae Hyun Jung et al.   Scientific Reports

Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma

(2019) Liang Zhang et al.   Science Translational Medicine

Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma

(2019) Neeraj Jain et al.   Science Translational Medicine

LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy

(2019) Mónica Pascual-García et al.   Nature Communications

Transcriptome Network Analysis Identifies CXCL13-CXCR5 Signaling Modules in the Prostate Tumor Immune Microenvironment

(2019) Adaugo Q. Ohandjo et al.   Scientific Reports

Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies

(2019) Xinjie Xu et al.   Frontiers in Immunology

Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients

(2019) Qinchuan Wang et al.   Journal for ImmunoTherapy of Cancer

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer

(2019) Paul Buderath et al.   Frontiers in Oncology

VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML

(2018) Liru Wang et al.   OncoImmunology

Highly elevated soluble Tim-3 levels correlate with increased hepatocellular carcinoma risk and poor survival of hepatocellular carcinoma patients in chronic hepatitis B virus infection

(2018) Fang Li et al.   Cancer Management and Research

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells

(2018) Xiu-Man Zhou et al.   Frontiers in Immunology

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation

(2017) Josefa A. Rodríguez   Oncology Letters

Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells

(2016) Dhifaf Sarhan et al.   CANCER RESEARCH

Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin

(2016) Junmin Zhou et al.   Scientific Reports

Myeloid Progenitor Cells in the Premetastatic Lung Promote Metastases by Inducing Mesenchymal to Epithelial Transition

(2012) D. Gao et al.   CANCER RESEARCH